01.01.08
Natrol, Inc., Chatsworth, CA, has signed a definitive merger agreement under which India-based Plethico Pharmaceuticals Limited will acquire all outstanding shares of Natrol’s common stock (or aggregate consideration of approximately $80.8 million). The two-step acquisition will be effected by means of a front-end, cash tender offer by a wholly owned subsidiary of Plethico for all of the outstanding shares of Natrol’s common stock, at $4.40 net per share in cash, followed by a second-step, cash-out merger in which untendered Natrol shares will be acquired at the same net cash price per share.